GITR is another novel stimulatory immune checkpoint in NK cells and T cells, whose agonism could promote anti-tumor immunity by reducing the regulatory T cells and stimulating the proliferation and activation of effector T cells (52). This evidence concerns the gene TNFRSF18 and neoplasm.